Brokerages forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will report sales of $9.00 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Heron Therapeutics’ earnings. The lowest sales estimate is $7.00 million and the highest is $10.00 million. Heron Therapeutics posted sales of $1.28 million in the same quarter last year, which suggests a positive year over year growth rate of 603.1%. The firm is expected to report its next quarterly earnings results on Thursday, February 22nd.
On average, analysts expect that Heron Therapeutics will report full year sales of $9.00 million for the current year, with estimates ranging from $27.71 million to $31.00 million. For the next fiscal year, analysts forecast that the business will report sales of $67.03 million per share, with estimates ranging from $65.00 million to $68.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at approximately $151,680. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 19.93% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of HRTX. Legal & General Group Plc lifted its position in Heron Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 2,383 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Heron Therapeutics during the third quarter valued at about $206,000. Jane Street Group LLC acquired a new position in shares of Heron Therapeutics during the third quarter valued at about $223,000. HighTower Advisors LLC raised its position in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the last quarter. Finally, Tudor Investment Corp ET AL raised its position in Heron Therapeutics by 10.2% in the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after purchasing an additional 1,724 shares in the last quarter. Hedge funds and other institutional investors own 98.37% of the company’s stock.
Heron Therapeutics (NASDAQ:HRTX) opened at $20.70 on Tuesday. The stock has a market capitalization of $1,130.00, a P/E ratio of -5.46 and a beta of 1.87. Heron Therapeutics has a one year low of $12.70 and a one year high of $24.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.